
The University of Washington's GAME Study recruits gamblers on GLP-1 drugs like Ozempic to assess changes in urges and behaviors. Qualified participants completing surveys receive a $50 gift card. Early research from UPenn and Boston University links these medications to reduced brain reward signals and lower risk appetite, as 29 million U.S. adults now use them.
SCCG Take — This research may identify new mechanisms for addressing gambling harm amid sports betting growth. Operators and regulators should monitor results for potential responsible gaming applications.
Researchers at the University of Washington are recruiting gamblers who take GLP-1 medications such as Ozempic or Wegovy. The Addictions, Drug & Alcohol Institute has launched the GAME Study to examine how these drugs affect betting behaviors.
The study targets individuals who have experienced gambling-related harm, either currently or before starting a GLP-1. Participants complete a brief online questionnaire, followed by a Zoom verification of identification and prescription. They then fill out a 30-minute survey on gambling urges, thoughts, and behaviors before and after beginning the medication. Those who complete all steps receive a $50 gift card.
Dr. Ty Lostutter, an associate professor at UW Psychiatry & Behavioral Sciences, described problem gambling as a rapidly growing public health crisis fueled by legalized sports betting. "There has been growing interest in the potential effects of these medications on addictive behaviors, but we still have much to learn about their relationship to gambling," said Lostutter. "We hope this study will help us better understand the experiences of individuals who gamble and are taking these medications, including whether they have noticed any changes in their gambling urges or behaviors."
Participant names and identifiable information remain separate from study data. Access is limited to certain study team members and authorized auditors from the UW or other agencies. The GAME Study is funded by an ADAI Small Grant.
Researchers at the University of Pennsylvania indicate GLP-1 medications "turn down" the brain's reward signals. This reduces cravings for food and other desired behaviors. Michael Platt, a neuroscientist and professor at the university's Wharton School, said long-term GLP-1 use leads to "some structural remodeling of the brain" that can influence financial decision-making and reduce an appetite for high-risk activities.
Boston University has published related early findings. "These drugs act on areas in the brain, like the mesolimbic system, which is involved in feelings of pleasure and motivation. This system plays a role in cravings for food, but also for other rewarding behaviors like drinking alcohol, gambling, or even shopping," said Dr. Ivania Rizo, an assistant professor of medicine at Boston University who is also the director of obesity medicine at Boston Medical Center.
In September, Gallup reported that an estimated 11% of the U.S. adult population is taking a GLP-1, or approximately 29 million people. The findings are drawn from multiple academic efforts, as reported by Casino.org.
Gaming, betting and prediction markets — the desk’s read, every weekday.
Subscribe →